A restrospective analysis of men with a serum PSA of 2.5–10 ng/ml and a previous negative diagnosis of prostate cancer following analysis of a biopsy sample has revealed that patients with both mild and moderate or marked prostate atrophy have a significantly lower risk of prostate cancer compared with that of patients with no prostate atrophy. This association was observed after follow-up durations of both 2 years and 4 years.
References
Moreira, D. M. et al. Baseline prostate atrophy is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy. J. Urol. 10.1016/j.juro.2015.05.103
Rights and permissions
About this article
Cite this article
Baseline atrophy reduces prostate cancer risk. Nat Rev Urol 12, 475 (2015). https://doi.org/10.1038/nrurol.2015.189
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.189
